Cisplatin chemotherapy-induced nausea and vomiting
Conditions
Interventions
Experimental group, control group:Routine antiemetic regimen + moxibustion at bilateral Zusanli (ST36) and bilateral Neiguan (PC6)
Control Group:Routine antiemetic regimen
Sponsors
Zigong City First People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) All subjects were confirmed to have malignant tumors by histopathology and were undergoing cisplatin plus paclitaxel regimen (TP regimen) chemotherapy; (2) 18 years = age 3 months.
Exclusion criteria
Exclusion criteria: (1) Individuals allergic to mugwort; (2) Individuals with skin breakdown at the acupuncture point; (3) Individuals experiencing nausea and vomiting due to vestibular dysfunction, gastrointestinal disorders, or other related conditions; (4) Individuals with cognitive impairments who are unable to cooperate; (5) Individuals who have participated in or are currently participating in other clinical trials within the past month; (6) Individuals undergoing chemotherapy within the past 48 hours or currently taking medications that may cause nausea and vomiting; (7) Individuals with unstable vital signs or extreme physical weakness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The severity and incidence rate of nausea and vomiting symptoms in patients post-treatment.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life Rating; | — |
Countries
China
Contacts
Public ContactYang Xiaoyan
Zigong City First People's Hospital
Outcome results
None listed